NCT00590395View on ClinicalTrials.gov

FDG-PET/CT in the Evaluation of Patients With Suspected Cholecystitis

NACompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

January 31, 2010

Study Completion Date

July 31, 2010

Conditions
Cholecystitis
Interventions
DRUG

18FDG (an FDA-approved radiopharmaceutical)

Route: Intravenous, Dosage: 5-10mCi, frequency: Single Administration

Trial Locations (1)

90048

Cedars-Sinai Medical Center, S. Mark Taper Foundation Imaging Center, Los Angeles

All Listed Sponsors
lead

Alan D. Waxman, M.D.

OTHER

NCT00590395 - FDG-PET/CT in the Evaluation of Patients With Suspected Cholecystitis | Biotech Hunter | Biotech Hunter